Patients with Crohn disease and the CT genotype may have be more likely to develop anti-adalimumab antibodes and therefore may have a decreased response to adalimumab therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to adalimumab.